Your fact-checks will appear here
The use of testosterone replacement therapy as a treatment for hypogonadism and erectile dysfunction.
The most consistent and replicated neuroendocrine change after orgasm in women is an elevation in plasma prolactin that is orgasm-dependent and typically sustained for about an hour; other candidate h...
Phosphodiesterase type 5 inhibitors (PDE5i) — oral drugs such as sildenafil — are the evidence‑based, guideline‑recommended first‑line pharmacologic treatment for most men with erectile dysfunction (E...
Evidence in the medical literature portrays a nuanced relationship: testosterone (T) affects libido and can improve erectile function in men with clinically low T, but large studies fail to show a dir...
Pelvic floor dysfunction alters the muscular, sensory, and autonomic scaffolding required for male orgasm, and its effects are amplified or mitigated by intertwined neurological and psychological fact...
Medical therapies that reliably and predictably increase semen volume in men over 50 are limited: treating identifiable medical causes—obstructive problems, prostate enlargement or medication effects—...
Current research shows two related threads: prostate structure and function change with age and these changes—plus treatments for prostate conditions—can influence libido, but the mechanisms are compl...
Testosterone drives penile growth during fetal development and puberty, but after physical maturity additional testosterone — whether prescribed TRT or over-the-counter boosters — does not meaningfull...
Dry orgasm is a symptom with multiple meanings—most commonly in men the experience of orgasm without ejaculate and in women the loss of lubrication and orgasmic response tied to vaginal atrophy—and ho...
Several medications can alter the usual coupling of orgasm and ejaculation—either by delaying or preventing semen emission while allowing the perceptual orgasm to occur, or by restoring orgasm when ej...